Latest News About Lilly

Here are the latest publicly reported updates on Lilly (Eli Lilly & Co.) as of May 2026:

• Lilly announced a substantial investment across its Indiana manufacturing footprint, including an additional $4.5 billion across two sites in Lebanon, Indiana, and the opening of a dedicated genetic medicine manufacturing facility in Lebanon. This signals a push to scale production for genetic therapies and related biologics.[1]
• The company reported strong first-quarter 2026 results, with revenue of about $19.8 billion (up around 56% year-over-year) and raised full-year revenue guidance to roughly $82.0–$85.0 billion; non-GAAP earnings per share guidance was raised to about $35.50–$37.00. These figures reflect its ongoing growth in diabetes, obesity, immune disease, and cancer therapies.[1]
• Strategic acquisitions and collaborations continue to shape Lilly’s pipeline, including plans to acquire Kelonia Therapeutics to expand in vivo CAR-T and genetic medicine capabilities, with potential total consideration up to $7.0 billion and an upfront payment of $3.25 billion; closing is anticipated in the second half of 2026 pending regulatory approvals.[1]
• Market-focused coverage notes Lilly’s efforts in obesity and diabetes treatment development, including regulatory interactions and potential fast-track FDA considerations for tirzepatide-based weight-loss indications, as well as ongoing competitive dynamics in the GLP-1 class with other major players.[2][3]

If you’d like, I can tailor a brief news digest, pull key quotes, or summarize implications for investors or patients. I can also provide a quick timeline of Lilly’s major 2026 milestones. Please tell me which format you prefer.